NCT01081262 · ADVERSE EVENTS

Adverse events

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Study treatment and up to 5 years after treatment discontinuation
Other-event reporting threshold: 0%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Arm I (Carboplatin and Paclitaxel) Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Carboplatin: Given IV Laboratory Biomarker Analysis: Correlative studies Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies	3 / 13	13 / 13	Not reported / Not reported
Arm II (Oxaliplatin and Capecitabine) Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Oxaliplatin: Given IV Quality-of-Life Assessment: Ancillary studies	4 / 13	13 / 13	Not reported / Not reported
Arm III (Carboplatin, Paclitaxel, Bevacizumab) Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Bevacizumab: Given IV Carboplatin: Given IV Laboratory Biomarker Analysis: Correlative studies Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies	2 / 13	13 / 13	Not reported / Not reported
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab) Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III. Bevacizumab: Given IV Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Oxaliplatin: Given IV Quality-of-Life Assessment: Ancillary studies	3 / 11	11 / 11	Not reported / Not reported

Group identifiers: EG000: Arm I (Carboplatin and Paclitaxel) · EG001: Arm II (Oxaliplatin and Capecitabine) · EG002: Arm III (Carboplatin, Paclitaxel, Bevacizumab) · EG003: Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Immune system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
1
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Allergic reaction
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
1
num At Risk
11
term
Anemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
1
num At Risk
11
term
Bleeding
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
1
num At Risk
11
term
Constipation
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
1
num At Risk
11
term
Diarrhea
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Respiratory, thoracic and mediastinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
1
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Dyspnea
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Fatigue
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Fever
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
1
num At Risk
11
term
GI perforation
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Hypomagnesemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Low Neutrophils
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Low Platelets

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Respiratory, thoracic and mediastinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
4
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Laryngeal Spasm
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
1
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Low Lymphocytes
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Psychiatric disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
2
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
1
num At Risk
11
term
Low Mood
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
7
num At Risk
13
group Id
EG001
num Affected
5
num At Risk
13
group Id
EG002
num Affected
4
num At Risk
13
group Id
EG003
num Affected
7
num At Risk
11
term
Low Neutrophils
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
8
num At Risk
13
group Id
EG001
num Affected
3
num At Risk
13
group Id
EG002
num Affected
5
num At Risk
13
group Id
EG003
num Affected
7
num At Risk
11
term
Low platelets
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
5
num At Risk
13
group Id
EG001
num Affected
5
num At Risk
13
group Id
EG002
num Affected
4
num At Risk
13
group Id
EG003
num Affected
6
num At Risk
11
term
Low White Blood Cells
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
1
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
3
num At Risk
11
term
Mucositis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
8
num At Risk
13
group Id
EG001
num Affected
8
num At Risk
13
group Id
EG002
num Affected
9
num At Risk
13
group Id
EG003
num Affected
9
num At Risk
11
term
Nausea
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
3
num At Risk
13
group Id
EG001
num Affected
2
num At Risk
13
group Id
EG002
num Affected
4
num At Risk
13
group Id
EG003
num Affected
9
num At Risk
11
term
Oral problems
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
4
num At Risk
13
group Id
EG001
num Affected
4
num At Risk
13
group Id
EG002
num Affected
7
num At Risk
13
group Id
EG003
num Affected
7
num At Risk
11
term
Other
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
8
num At Risk
13
group Id
EG001
num Affected
6
num At Risk
13
group Id
EG002
num Affected
7
num At Risk
13
group Id
EG003
num Affected
7
num At Risk
11
term
Other GI Problems
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
9
num At Risk
13
group Id
EG001
num Affected
6
num At Risk
13
group Id
EG002
num Affected
7
num At Risk
13
group Id
EG003
num Affected
7
num At Risk
11
term
Pain

Complete source fields

event Groups

description
Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Carboplatin: Given IV Laboratory Biomarker Analysis: Correlative studies Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies
id
EG000
other Num Affected
13
other Num At Risk
13
serious Num Affected
3
serious Num At Risk
13
title
Arm I (Carboplatin and Paclitaxel)
description
Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Oxaliplatin: Given IV Quality-of-Life Assessment: Ancillary studies
id
EG001
other Num Affected
13
other Num At Risk
13
serious Num Affected
4
serious Num At Risk
13
title
Arm II (Oxaliplatin and Capecitabine)
description
Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Bevacizumab: Given IV Carboplatin: Given IV Laboratory Biomarker Analysis: Correlative studies Paclitaxel: Given IV Quality-of-Life Assessment: Ancillary studies
id
EG002
other Num Affected
13
other Num At Risk
13
serious Num Affected
2
serious Num At Risk
13
title
Arm III (Carboplatin, Paclitaxel, Bevacizumab)
description
Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III. Bevacizumab: Given IV Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Oxaliplatin: Given IV Quality-of-Life Assessment: Ancillary studies
id
EG003
other Num Affected
11
other Num At Risk
11
serious Num Affected
3
serious Num At Risk
11
title
Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)

frequency Threshold

other Events

assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Respiratory, thoracic and mediastinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
4
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Laryngeal Spasm
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
1
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Low Lymphocytes
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Psychiatric disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
2
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
1
num At Risk
11
term
Low Mood
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
7
num At Risk
13
group Id
EG001
num Affected
5
num At Risk
13
group Id
EG002
num Affected
4
num At Risk
13
group Id
EG003
num Affected
7
num At Risk
11
term
Low Neutrophils
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
8
num At Risk
13
group Id
EG001
num Affected
3
num At Risk
13
group Id
EG002
num Affected
5
num At Risk
13
group Id
EG003
num Affected
7
num At Risk
11
term
Low platelets
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
5
num At Risk
13
group Id
EG001
num Affected
5
num At Risk
13
group Id
EG002
num Affected
4
num At Risk
13
group Id
EG003
num Affected
6
num At Risk
11
term
Low White Blood Cells
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
1
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
3
num At Risk
11
term
Mucositis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
8
num At Risk
13
group Id
EG001
num Affected
8
num At Risk
13
group Id
EG002
num Affected
9
num At Risk
13
group Id
EG003
num Affected
9
num At Risk
11
term
Nausea
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
3
num At Risk
13
group Id
EG001
num Affected
2
num At Risk
13
group Id
EG002
num Affected
4
num At Risk
13
group Id
EG003
num Affected
9
num At Risk
11
term
Oral problems
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
4
num At Risk
13
group Id
EG001
num Affected
4
num At Risk
13
group Id
EG002
num Affected
7
num At Risk
13
group Id
EG003
num Affected
7
num At Risk
11
term
Other
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
8
num At Risk
13
group Id
EG001
num Affected
6
num At Risk
13
group Id
EG002
num Affected
7
num At Risk
13
group Id
EG003
num Affected
7
num At Risk
11
term
Other GI Problems
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
9
num At Risk
13
group Id
EG001
num Affected
6
num At Risk
13
group Id
EG002
num Affected
7
num At Risk
13
group Id
EG003
num Affected
7
num At Risk
11
term
Pain

serious Events

assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Immune system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
1
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Allergic reaction
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
1
num At Risk
11
term
Anemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
1
num At Risk
11
term
Bleeding
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
1
num At Risk
11
term
Constipation
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
1
num At Risk
11
term
Diarrhea
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Respiratory, thoracic and mediastinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
1
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Dyspnea
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Fatigue
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Fever
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
1
num At Risk
11
term
GI perforation
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
0
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Hypomagnesemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
1
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Low Neutrophils
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
CTCAE (4.0)
stats
group Id
EG000
num Affected
1
num At Risk
13
group Id
EG001
num Affected
0
num At Risk
13
group Id
EG002
num Affected
0
num At Risk
13
group Id
EG003
num Affected
0
num At Risk
11
term
Low Platelets

time Frame

Study treatment and up to 5 years after treatment discontinuation

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice